DermBiont

Topical Bacterial Products

SM-030 Clin2 photodamage hyperpigmentation

DermBiont is a dermatology company developing therapeutics to treat and prevent skin diseases. Important to healthy skin is the dermal microbiome which includes millions of bacteria, fungi and viruses. DermBiont is developing targeted small molecule therapeutics (pre-, pro- and post-biotics) that can repair dysbiosis of the microbiome. The current pipeline includes small molecules in phase 2 clinical trials for dermatitis, keratoses and photodamage hyperpigmentation. DermBiont’s therapeutics are topical and address the root cause of the skin diseases.